velasof tablets uses

1. velasof tablets uses Description Description Velasof is the fixed dose combination of these two most widely used anti-viral agents. Sofosbuvir & Velpatasvir are directly acting anti-viral agents which are involved in the treatment of chronic hepatitis C viral infection. Sofosbuvir is usually combined with other anti-viral agent for exhibiting the prominent effects.Velasof is the FDA approved product, which is used in chronic HCV condition. Velasof should be used in genotype I, II, III, IV, V or VI associated hepatitis C viral infections. Buy velasof tablets (Sofosbuvir 400 mg & Velpatasvir 100 mg), It is the fixed dose combination of these two most widely used anti viral drugs, Sofosbuvir & Velpatasvir are directly acting anti-viral agents which are involved in the treatment of chronic hepatitis C viral infection @ Applepharmaceuticals

2. PRODUCT DETAILS PRODUCT DETAILS Brand Name :Velasof Active components : Sofosbuvir & Velpatasvir Strength of the components : 400mg & 100mg respectively Package : 28 tablets in a container Manufactured by: Hetero Drugs Ltd Classified as: Anti-viral drugs

3. DOSAGE BEFORE THE TREATMENT DOSAGE BEFORE THE TREATMENT •Examine the patients thoroughly, before initiating the treatment with HCV anti-viral agents. Care should be taken while using HCV medication in patients with HCV/HIV-1co infections, in this case HBV reactivation occurs. •Velasof tablets are recommended for chronic condition of hepatitis C viral infection related to genotype 1, 2, 3, 4, 5 or 6. The dosing of Velasof; The usual recommended dose of Velasof is, one tablet should be administered orally as a single dose. •Velasof tablet consist of 100mg of Velpatasvir & 400mg of Sofosbuvir WORKS WORKS •Sofosbuvir is a NS5B protein inhibitor, protein is essential for viral production. Sofosbuvir is a prodrug form, which get converted into active uridine triphosphate form which is required for anti-viral activity. • This dynamic active moiety is get inserted into HCV RNA with the help of NS5B polymerase and leads as chain eliminator. •Velpatasvir is pharmacologically acts as NS5A inhibitor; this protein is required for HCV viral production. Velpatasvir is involved its action in viral production process.

4. DRUG INTERACTION DRUG INTERACTION •Velasof tablets are combined with P-gp inducers either potent or moderate, causes loss of activity of Velasof by decreasing the sofosbuvir plasma concentration. •Velasof tablets co administered with P-gp or BCRP inhibitors, leads to increase the exposure of adverse effects of these substrates. •Velasof combined with warfarin causes variation in both prothrombin time & INR values. •Velasof co administered with acid reducing agents causes decreasing the effect of concentration of sofosbuvir & Velpatasvir leads to loss of activity of Velasof. •Velasof tablets combined with amiodarone leads to cause bradycardia. Velasof tablets co administered with anti-convulsants, or anti-mycobacterials, causes decreasing concentration of sofosbuvir & Velpatasvir. •Velasof with st Johns wort causes losing the anti-viral activity of Velasof by decreasing the concentration of either sofosbuvir or Velpatasvir. •Velasof combined with HMG CoA reductase inhibitors causes increasing the concentration of these drugs.

5. CONTRAINDICATION CONTRAINDICATION Velasof is contraindicated to pregnancy condition due to concomitant use with ribavirin. Some anaphylactic reactions are acquired during the therapy, while the patients are contraindicated to the component of Velasof.